Research and regulatory reference
IGF-1 LR3
A source-linked reference on the identity and evidence context of IGF-1 LR3. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Identity
IGF-1 LR3, also called long arginine-3 IGF-I, is a modified IGF-I analogue. A PubChem substance record lists those aliases, and a primary rat study describes the LR3 form as having arginine at residue 3 with an N-terminal extension.
Sources: PubChem, National Library of Medicine, PubMed, National Library of Medicine
A named substance and a finished product are different claims. The name does not verify formulation, concentration, purity or equivalence to material used in a study.
Research context
The cited primary study examined IGF-I variants in streptozotocin-induced diabetic rats. It is animal research and does not establish a clinical indication, effectiveness or safety in people.
Sources: PubMed, National Library of Medicine
The chemical identity record supports naming and aliases only. It is not evidence of a health outcome, product quality or personal suitability.
Evidence boundary
Animal findings for this modified analogue cannot be transferred to people, untested products or other IGF-I forms. No recommendation or dosing instruction is provided.
The appropriate conclusion is limited to the cited identity record and rat study.
Published sources
- Long-(arg3)insulin-like growth factor-I
PubChem, National Library of Medicine. Current substance record; accessed 6 September 2026.
Supports: Aliases including Long R3 insulin-like growth factor-I and IGF-1 LR3 for the named substance record.
- Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects
PubMed, National Library of Medicine. Published 1993; accessed 6 September 2026.
Supports: The LR3-IGF-I modified identity, described as arginine at residue 3 with an N-terminal extension, and an animal-study context.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.